Leishmaniasis

Human Vaccines

Volumn 7, Issue 11, 2011, Pages 1204-1214

  Kedzierski, Lukasz ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cutaneous leishmaniasis; Immune response; Leishmania; Vaccine; Visceral leishmaniasis

Indexed keywords

ACIDIC RIBOSOMAL PROTEIN P0; AMASTIGOTE CYSTEINE PROTEINASE; AMASTIGOTE MEMBRANE PROTEIN P4; AMASTIGOTE MEMBRANE PROTEIN P8; AMASTIGOTE PROTEIN LCR1; CYSTEINE PROTEINASE A2; DNA VACCINE NH36; DRUG CARRIER; GLYCOPROTEIN GP 46; GLYCOPROTEIN LEISHMANIOLYSIN GP 63; HYDROPHILIC ACYLATED SURFACE PROTEIN B1; KINETOPLASTID MEMBRANE PROTEIN 11; LEISH PROTEIN 110F; LEISH PROTEIN 111F; LEISH TEC; LEISH TEC VACCINE; LEISHMANIA HOMOLOG FOR RECEPTORS OF ACTIVATED C KINASE; LEISHMANIA VACCINE; LEISHMANIAL ANTIGEN ORFF; LEISHMUNE; LEISHMUNE VACCINE; NANOPARTICLE; PARAFLAGELLAR ROD PROTEIN 2; PARASITE SURFACE ANTIGEN 2; PROTECTIVE AGENT; PROTEOPHOSPHOGLYCAN; SUPEROXIDE DISMUTASE B1; UNCLASSIFIED DRUG;

CANINE VISCERAL LEISHMANIASIS; COST EFFECTIVENESS ANALYSIS; DOG DISEASE; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; HUMAN; INFECTION CONTROL; LEISHMANIASIS; LIPOSOMAL DELIVERY; NONHUMAN; PROTEOMICS; REVIEW; SKIN LEISHMANIASIS; VACCINATION; VISCERAL LEISHMANIASIS;

EID: 81855224508     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.11.17752     Document Type: Review

References (150)

1. Handman E. Cell biology of Leishmania. Adv Parasitol 1999; 44:1-39; PMID:10563394; DOI:10.1016/ S0065-308X(08)60229-8.
2. Chevalier B, Carmoi T, Sagui E, Carrette P, Petit D, De Mauleon P, et al. Report of the first cases of cutaneous leishmaniasis in East Timor. Clin Infect Dis 2000; 30:840; PMID:10816165; DOI:10.1086/313789.
3. Kongkaew W, Siriarayaporn P, Leelayoova S, Supparatpinyo K, Areechokchai D, Duang-ngern P, et al. Autochthonous visceral leishmaniasis: a report of a second case in Thailand. Southeast Asian J Trop Med Public Health 2007; 38:8-12; PMID:17539239.
4. Rose K, Curtis J, Baldwin T, Mathis A, Kumar B, Sakthianandeswaren A, et al. Cutaneous leishmaniasis in red kangaroos: isolation and characterisation of the causative organisms. Int J Parasitol 2004; 34:655-64; PMID:15111087; DOI:10.1016/j.ijpara.2004.03.001.
5. Modabber F. Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents 2010; 36:58-61; PMID:20801000; DOI:10.1016/j.ijantimicag. 2010.06.024.
6. Dantas-Torres F. Canine leishmaniosis in South America. Parasit Vectors 2009; 2:1; PMID:19426440; DOI:10.1186/1756-3305-2-S1-S1.
7. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2008; 2:313; PMID:18958165; DOI:10.1371/journal.pntd.0000313.
8. Patz JA, Graczyk TK, Geller N, Vittor AY. Effects of environmental change on emerging parasitic diseases. Int J Parasitol 2000; 30:1395-405; PMID:11113264; DOI:10.1016/S0020-7519(00)00141-7.
9. Pavli A, Maltezou HC. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis 2010; 14:1032-9; PMID:20952234; DOI:10.1016/j.ijid.2010.06.019.
10. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 2009; 16:599-614; PMID:19199925; DOI:10.2174/ 092986709787458489.
11. Kedzierski L, Zhu Y, Handman E. Leishmania vaccines: progress and problems. Parasitology 2006; 133:87-112; PMID:17274851; DOI:10.1017/ S0031182006001831.
12. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 2008; 26:6759-67; PMID:18950671; DOI:10.1016/j.vaccine.2008.09.085.
13. Costa CH, Peters NC, Maruyama SR, de Brito EC Jr, Santos IK. Vaccines for the leishmaniases: proposals for a research agenda. PLoS Negl Trop Dis 2011; 5:943; PMID:21468307; DOI:10.1371/journal. pntd.0000943.
14. Bebars MA, el Serougi AO, Makled KM, Mikhael EM, Abou Gamra MM, el Sherbiny M, et al. An experimental vaccine providing heterologous protection for Leishmania species in murine model. J Egypt Soc Parasitol 2000; 30:137-56; PMID:10786026.
15. Goto Y, Bhatia A, Raman VS, Liang H, Mohamath R, Picone AF, et al. KSAC: the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol 2011; 18:1118-24; PMID:21632891; DOI:10.1128/CVI.05024-11.
16. Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet 2007; 39:839-47; PMID:17572675; DOI:10.1038/ng2053.
17. Lainson R, Shaw JJ. Leishmaniasis in Brazil: XII. Observations on cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, L. m. amazonensis, L. braziliensis braziliensis, L. b. guyanensis and L. b. panamensis. J Trop Med Hyg 1977; 80:29-35; PMID:405504.
18. Porrozzi R, Teva A, Amaral VF, Santos da Costa MV, Grimaldi G Jr. Cross-immunity experiments between different species or strains of Leishmania in rhesus macaques (Macaca mulatta). Am J Trop Med Hyg 2004; 71:297-305; PMID:15381810.
19. McMahon-Pratt D, Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev 2004; 201:206-24; PMID:15361243; DOI:10.1111/j.0105-2896.2004.00190.x.
20. Ilg T. Lipophosphoglycan is not required for infection of macrophages or mice by Leishmania mexicana. EMBO J 2000; 19:1953-62; PMID:10790362; DOI:10.1093/emboj/19.9.1953.
21. Späth GF, Epstein L, Leader B, Singer SM, Avila HA, Turco SJ, et al. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc Natl Acad Sci USA 2000; 97:9258-63; PMID:10908670; DOI:10.1073/pnas.160257897.
22. + T cells in pathogenesis associated with Leishmania amazonensis infection. J Immunol 1997; 158:5374-83; PMID:9164958.
23. Okwor I, Liu D, Beverley SM, Uzonna JE. Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. Proc Natl Acad Sci USA 2009; 106:13951-6; PMID:19666482; DOI:10.1073/pnas.0905184106.
24. Nagill R, Kaur S. Vaccine candidates for leishmaniasis: A review. Int Immunopharmacol 2011; In press; PMID:21616175; DOI:10.1016/j. intimp.2011.05.008.
25. Russo DM, Burns JM Jr, Carvalho EM, Armitage RJ, Grabstein KH, Button LL, et al. Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol 1991; 147:3575-80; PMID:1940356.
26. Kaur T, Sobti RC, Kaur S. Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB/c mice. Parasite Immunol 2011; 33:95-103; PMID:21226722; DOI:10.1111/j.1365-3024.2010.01253.x.
27. Mazumder S, Maji M, Das A, Ali N. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS ONE 2011; 6:14644; PMID:21311597; DOI:10.1371/journal. pone.0014644.
28. McMahon-Pratt D, Traub-Cseko Y, Lohman KL, Rogers DD, Beverley SM. Loss of the GP46/M-2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex. Mol Biochem Parasitol 1992; 50:151-60; PMID:1542309; DOI:10.1016/0166-6851(92)90252-F.
29. Kedzierski L, Montgomery J, Bullen D, Curtis J, Gardiner E, Jimenez-Ruiz A, et al. A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3. J Immunol 2004; 172:4902-6; PMID:15067069.
30. Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995; 63:4261-7; PMID:7591056.
31. Sjölander A, Baldwin TM, Curtis JM, Bengtsson KL, Handman E. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 1998; 16:2077-84; PMID:9796067; DOI:10.1016/S0264-410X(98)00075-9.
32. Sjölander A, Baldwin TM, Curtis JM, Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol 1998; 160:3949-57; PMID:9558102.
33. Handman E, Noormohammadi AH, Curtis JM, Baldwin T, Sjolander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine 2000; 18:3011-7; PMID:10825604; DOI:10.1016/S0264-410X(00)00109-2.
34. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang ZE, et al. Expression cloning of a protective Leishmania antigen. Science 1995; 268:563-6; PMID:7725103; DOI:10.1126/science.7725103.
35. + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997; 6:541-9; PMID:9175832; DOI:10.1016/S1074-7613(00)80342-8.
36. Julia V, Rassoulzadegan M, Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996; 274:421-3; PMID:8832890; DOI:10.1126/science.274.5286.421.
37. Kronenberg K, Brosch S, Butsch F, Tada Y, Shibagaki N, Udey MC, et al. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cellmediated immunity against Leishmania major. J Invest Dermatol 2010; 130:2602-10; PMID:20574442; DOI:10.1038/jid.2010.171.
38. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001; 69:4719-25; PMID:11447143; DOI:10.1128/ IAI.69.8.4719-25.2001.
39. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005; 23:3716-25; PMID:15882533; DOI:10.1016/j.vaccine. 2005.02.009.
40. Soong L, Duboise SM, Kima P, McMahon-Pratt D. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 1995; 63:3559-66; PMID:7642292.
41. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 2005; 174:7160-71; PMID:15905560.
42. Streit JA, Recker TJ, Donelson JE, Wilson ME. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp Parasitol 2000; 94:33-41; PMID:10631078; DOI:10.1006/expr.1999.4459.
43. Stäger S, Smith DF, Kaye PM. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000; 165:7064-71; PMID:11120835.
44. Tewary P, Jain M, Sahani MH, Saxena S, Madhubala R. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis 2005; 191:2130-7; PMID:15898000; DOI:10.1086/430348.
45. Iborra S, Soto M, Carrion J, Nieto A, Fernandez E, Alonso C, et al. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect Immun 2003; 71:6562-72; PMID:14573678; DOI:10.1128/IAI.71.11.6562-72.2003.
46. Saravia NG, Hazbon MH, Osorio Y, Valderrama L, Walker J, Santrich C, et al. Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana. Vaccine 2005; 23:984-95; PMID:15620471; DOI:10.1016/j.vaccine.2004.07. 044.
47. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 2005; 73:812-9; PMID:15664920; DOI:10.1128/ IAI.73.2.812-9.2005.
48. Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, et al. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1- type immunoprotective response against experimental visceral leishmaniasis. J Immunol 2009; 183:470-9; PMID:19542458; DOI:10.4049/jimmunol.0900265.
49. Bhowmick S, Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccinemediated protection in visceral leishmaniasis. PLoS ONE 2009; 4:5820; PMID:19503834; DOI:10.1371/ journal.pone.0005820.
50. Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection. J Parasitol 2010; 96:929-36; PMID:20950100; DOI:10.1645/GE-2360.1.
51. Masih S, Arora SK, Vasishta RK. Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis. Exp Parasitol 2011; 129:55-64; PMID:21640106; DOI:10.1016/j.exppara. 2011.05.014.
52. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005; 21:244-9; PMID:15837614; DOI:10.1016/j.pt.2005.03.006.
53. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002; 20:3292-303; PMID:12213399; DOI:10.1016/S0264-410X(02)00302-X.
54. + T cells. Infect Immun 2007; 75:4648-54; PMID:17606603; DOI:10.1128/IAI.00394-07.
55. Gradoni L, Foglia Manzillo V, Pagano A, Piantedosi D, De Luna R, Gramiccia M, et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 2005; 23:5245-51; PMID:16054272; DOI:10.1016/j. vaccine.2005.07.001.
56. Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral- Sampaio G, de Jesus RS, et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f + MPLSE. Vaccine 2010; 28:3333-40; PMID:20206667; DOI:10.1016/j.vaccine.2010.02. 089.
57. Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D, et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009; 27:7036-45; PMID:19786136; DOI:10.1016/j.vaccine. 2009.09.066.
58. Miret J, Nascimento E, Sampaio W, Franca JC, Fujiwara RT, Vale A, et al. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 2008; 26:1585-94; PMID:18328956; DOI:10.1016/j.vaccine. 2008.01.026.
59. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011; 29:3531-7; PMID:21414377; DOI:10.1016/j.vaccine.2011.02.096.
60. Llanos-Cuentas A, Calderon W, Cruz M, Ashman JA, Alves FP, Coler RN, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPLSE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 2010; 28:7427-35; PMID:20851080; DOI:10.1016/j.vaccine.2010.08.092.
61. Nascimento E, Fernandes DF, Vieira EP, Campos- Neto A, Ashman JA, Alves FP, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010; 28:6581-7; PMID:20688040; DOI:10.1016/j.vaccine. 2010.07.063.
62. Andrade BB, de Oliveira CI, Brodskyn CI, Barral A, Barral-Netto M. Role of sand fly saliva in human and experimental leishmaniasis: current insights. Scand J Immunol 2007; 66:122-7; PMID:17635789; DOI:10.1111/j.1365-3083.2007. 01964.x.
63. Kamhawi S, Belkaid Y, Modi G, Rowton E, Sacks D. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000; 290:1351-4; PMID:11082061; DOI:10.1126/science. 290.5495.1351.
64. Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol 2001; 167:5226-30; PMID:11673536.
65. Valenzuela JG, Belkaid Y, Garfield MK, Mendez S, Kamhawi S, Rowton ED, et al. Toward a defined anti- Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001; 194:331-42; PMID:11489952; DOI:10.1084/ jem.194.3.331.
66. Gomes R, Teixeira C, Teixeira MJ, Oliveira F, Menezes MJ, Silva C, et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci USA 2008; 105:7845-50; PMID:18509051; DOI:10.1073/pnas.0712153105.
67. Collin N, Gomes R, Teixeira C, Cheng L, Laughinghouse A, Ward JM, et al. Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania. PLoS Pathog 2009; 5:1000441; PMID:19461875; DOI:10.1371/journal.ppat.1000441.
68. Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, Sacks DL. Vector transmission of leishmania abrogates vaccine-induced protective immunity. PLoS Pathog 2009; 5:1000484; PMID:19543375; DOI:10.1371/journal.ppat.1000484.
69. Gomes RB, Brodskyn C, de Oliveira CI, Costa J, Miranda JC, Caldas A, et al. Seroconversion against Lutzomyia longipalpis saliva concurrent with the development of anti-Leishmania chagasi delayedtype hypersensitivity. J Infect Dis 2002; 186:1530-4; PMID:12404176; DOI:10.1086/344733.
70. Rohoušová I, Hostomska J, Vlkova M, Kobets T, Lipoldova M, Volf P. The protective effect against Leishmania infection conferred by sand fly bites is limited to short-term exposure. Int J Parasitol 2011; 41:481-5; PMID:21310158; DOI:10.1016/j.ijpara. 2011.01.003.
71. Ahmed SB, Kaabi B, Chelbi I, Derbali M, Cherni S, Laouini D, et al. Lack of protection of pre-immunization with saliva of long-term colonized Phlebotomus papatasi against experimental challenge with Leishmania major and saliva of wild-caught P. papatasi. Am J Trop Med Hyg 2010; 83:512-4; PMID:20810812; DOI:10.4269/ajtmh.2010; 09-0687.
72. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995; 92:10267-71; PMID:7479765; DOI:10.1073/ pnas.92.22.10267.
73. Amaral VF, Teva A, Oliveira-Neto MP, Silva AJ, Pereira MS, Cupolillo E, et al. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem Inst Oswaldo Cruz 2002; 97:1041-8; PMID:12471434; DOI:10.1590/S0074-02762002000700019.
74. Alexander J, Coombs GH, Mottram JC. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998; 161:6794-801; PMID:9862710.
75. Saravia NG, Escorcia B, Osorio Y, Valderrama L, Brooks D, Arteaga L, et al. Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models. Vaccine 2006; 24:4247-59; PMID:16216395; DOI:10.1016/j.vaccine.2005.05.045.
76. Uzonna JE, Spath GF, Beverley SM, Scott P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 2004; 172:3793-7; PMID:15004184.
77. Kébaïer C, Uzonna J, Beverley SM, Scott P. Immunization with persistent attenuated (delta)lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice. Infect Immun 2006; 74:777-80; PMID:16369039; DOI:10.1128/ IAI.74.1.777-80.2006.
78. Späth GF, Lye LF, Segawa H, Turco SJ, Beverley SM. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect Immun 2004; 72:3622-7; PMID:15155672; DOI:10.1128/IAI.72.6.3622-7.2004.
79. Zaph C, Uzonna J, Beverley SM, Scott P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 2004; 10:1104-10; PMID:15448686; DOI:10.1038/ nm1108.
80. Selvapandiyan A, Debrabant A, Duncan R, Muller J, Salotra P, Sreenivas G, et al. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J Biol Chem 2004; 279:25703-10; PMID:15084606; DOI:10.1074/jbc.M402794200.
81. Selvapandiyan A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J Immunol 2009; 183:1813-20; PMID:19592661; DOI:10.4049/ jimmunol.0900276.
82. Kedzierski L, Curtis JM, Doherty PC, Handman E, Kedzierska K. Decreased IL-10 and IL-13 production and increased CD44 hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. Eur J Immunol 2008; 38:3090-100; PMID:18924210; DOI:10.1002/eji.200838423.
83. Silvestre R, Cordeiro-Da-Silva A, Santarem N, Vergnes B, Sereno D, Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFNgamma/IL-10 pattern that correlates with protection. J Immunol 2007; 179:3161-70; PMID:17709531.
84. Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 2005; 73:6372-82; PMID:16177308; DOI:10.1128/ IAI.73.10.6372-82.2005.
85. Lima LV, Carneiro LA, Campos MB, Chagas EJ, Laurenti MD, Corbett CE, et al. Canine visceral leishmaniasis due to Leishmania (L.) infantum chagasi in Amazonian Brazil: comparison of the parasite density from the skin, lymph node and visceral tissues between symptomatic and asymptomatic, seropositive dogs. Rev Inst Med Trop Sao Paulo 2010; 52:259-66; PMID:21049230.
86. Postigo JA. Leishmaniasis in the World Health Organization eastern Mediterranean Region. Int J Antimicrob Agents 2010; 36:62-5; PMID:20728317; DOI:10.1016/j.ijantimicag.2010.06.023.
87. Ashford RW. The leishmaniases as emerging and reemerging zoonoses. Int J Parasitol 2000; 30:1269-81; PMID:11113254; DOI:10.1016/S0020-7519(00)00136-3.
88. Biglino A, Bolla C, Concialdi E, Trisciuoglio A, Romano A, Ferroglio E. Asymptomatic Leishmania infantum infection in an area of northwestern Italy (Piedmont region) where such infections are traditionally nonendemic. J Clin Microbiol 2010; 48:131-6; PMID:19923480; DOI:10.1128/JCM.00416-09.
89. Schantz PM, Steurer FJ, Duprey ZH, Kurpel KP, Barr SC, Jackson JE, et al. Autochthonous visceral leishmaniasis in dogs in North America. J Am Vet Med Assoc 2005; 226:1316-22; PMID:15844420; DOI:10.2460/ javma.2005.226.1316.
90. Ready PD. Leishmaniasis emergence in Europe. Euro Surveill 2010; 15:19505; PMID:20403308.
91. Baneth G, Shaw SE. Chemotherapy of canine leishmaniosis. Vet Parasitol 2002; 106:315-24; PMID:12079737; DOI:10.1016/S0304-4017(02)00115-2.
92. Palatnik-de-Sousa CB, dos Santos WR, Franca-Silva JC, da Costa RT, Reis AB, Palatnik M, et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg 2001; 65:510-7; PMID:11716106.
93. Courtenay O, Quinnell RJ, Garcez LM, Shaw JJ, Dye C. Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 2002; 186:1314-20; PMID:12402201; DOI:10.1086/344312.
94. Reithinger R, Coleman PG, Alexander B, Vieira EP, Assis G, Davies CR. Are insecticide-impregnated dog collars a feasible alternative to dog culling as a strategy for controlling canine visceral leishmaniasis in Brazil? Int J Parasitol 2004; 34:55-62; PMID:14711590; DOI:10.1016/j.ijpara.2003.09.006.
95. Poot J, Janssen LH, van Kasteren-westerneng TJ, van der Heijden-Liefkens KH, Schijns VE, Heckeroth A. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants. Vaccine 2009; 27:4439-46; PMID:19500553; DOI:10.1016/j.vaccine.2009.05.043.
96. Bahia D, Gontijo NF, Leon IR, Perales J, Pereira MH, Oliveira G, et al. Antibodies from dogs with canine visceral leishmaniasis recognise two proteins from the saliva of Lutzomyia longipalpis. Parasitol Res 2007; 100:449-54; PMID:17058112; DOI:10.1007/s00436-006-0307-8.
97. Giunchetti RC, Correa-Oliveira R, Martins-Filho OA, Teixeira-Carvalho A, Roatt BM, de Oliveira Aguiar-Soares RD, et al. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. Vaccine 2008; 26:623-38; PMID:18180079; DOI:10.1016/j.vaccine. 2007.11.057.
98. Dantas-Torres F. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet Parasitol 2006; 141:1-8; PMID:16750885; DOI:10.1016/j.vetpar.2006.05.001.
99. Palatnik-de-Sousa CB, Dutra HS, Borojevic R. Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML). Acta Trop 1993; 53:59-72; PMID:8096110; DOI:10.1016/0001-706X(93) 90006-W.
100. da Silva VO, Borja-Cabrera GP, Correia Pontes NN, de Souza EP, Luz KG, Palatnik M, et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 2000; 19:1082-92; PMID:11137242; DOI:10.1016/S0264-410X(00)00339-X.
101. Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Souza E, Santos WR, Gomes EM, et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 2002; 20:3277-84; PMID:12213397; DOI:10.1016/S0264- 410X(02)00294-3.
102. Nogueira FS, Moreira MA, Borja-Cabrera GP, Santos FN, Menz I, Parra LE, et al. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 2005; 23:4805-10; PMID:16011864; DOI:10.1016/j. vaccine.2005.05.011.
103. Borja-Cabrera GP, Cruz Mendes A, Paraguai de Souza E, Hashimoto Okada LY, de A Trivellato FA, Kawasaki JK, et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004; 22:2234-43; PMID:15149782; DOI:10.1016/j. vaccine.2003.11.039.
104. Borja-Cabrera GP, Santos FN, Santos FB, Trivellato FA, Kawasaki JK, Costa AC, et al. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Vaccine 2010; 28:597-603; PMID:19800443; DOI:10.1016/j.vaccine. 2009.09.071.
105. Palatnik-de-Sousa CB, Silva-Antunes I, Morgado Ade A, Menz I, Palatnik M, Lavor C. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Vaccine 2009; 27:3505-12; PMID:19464528; DOI:10.1016/j.vaccine.2009.03.045.
106. Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, Melo MN, et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008; 26:5888-95; PMID:18786587; DOI:10.1016/j.vaccine.2008.05.095.
107. + T cells. Vaccine 2008; 26:4585-93; PMID:18588933; DOI:10.1016/j.vaccine.2008.05.091.
108. Okwor I, Uzonna J. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol Res 2008; 41:123-36; PMID:18389179; DOI:10.1007/s12026-008- 8016-2.
109. Uzonna JE, Wei G, Yurkowski D, Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination and reactivation disease. J Immunol 2001; 167:6967-74; PMID:11739516.
110. Birnbaum R, Craft N. Innate immunity and Leishmania vaccination strategies. Dermatol Clin 2011; 29:89-102; PMID:21095533; DOI:10.1016/j.det. 2010.08.014.
111. Forgber M, Basu R, Roychoudhury K, Theinert S, Roy S, Sundar S, et al. Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS ONE 2006; 1:40; PMID:17183669; DOI:10.1371/journal.pone. 0000040.
112. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010; 33:530-41; PMID:21029963; DOI:10.1016/j.immuni. 2010.09.017.
113. Schroeder J, Aebischer T. Vaccines for Leishmaniasis: From proteome to vaccine candidates. Hum Vaccin 2011; 7:10-5; PMID:21245661; DOI:10.4161/hv.7.0. 14556.
114. Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 2008; 9:22; PMID:19091022; DOI:10.1186/1471-2105-9-S12-S22.
115. Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 2008; 9:8; PMID:18366636; DOI:10.1186/1471-2172-9-8.
116. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010; 8:62-73; PMID:19966816; DOI:10.1038/ nrmicro2240.
117. de Goede AL, Boers PH, Dekker LJ, Osterhaus AD, Gruters RA, Rimmelzwaan GF. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag. Vaccine 2009; 27:5735-9; PMID:19647812; DOI:10.1016/j.vaccine.2009.07. 032.
118. Stukova MA, Sereinig S, Zabolotnyh NV, Ferko B, Kittel C, Romanova J, et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) 2006; 86:236-46; PMID:16677861; DOI:10.1016/j. tube.2006.01.010.
119. + responses in mice. Proc Natl Acad Sci USA 1998; 95:3954-9; PMID:9520474; DOI:10.1073/pnas.95.7.3954.
120. Zheng H, Palese P, Garcia-Sastre A. Antitumor properties of influenza virus vectors. Cancer Res 2000; 60:6972-6; PMID:11156398.
121. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002; 20:3165- 70; PMID:12163268; DOI:10.1016/S0264-410X(02)00268-2.
122. Maassab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 1999; 9:237-44; PMID:10578119; DOI:10.1002/ (SICI)1099-1654(199910/12)9:4〈237::AIDRMV252〉 3.0.CO;2-G.
123. Mishin VP, Nedyalkova MS, Hayden FG, Gubareva LV. Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model. Vaccine 2005; 23:2922-7; PMID:15780741; DOI:10.1016/j.vaccine.2004.11.058.
124. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4:145-60; PMID:15688077; DOI:10.1038/nrd1632.
125. + T cells and induce potent antitumor immunity. J Immunol 2006; 177:2324-30; PMID:16887993.
126. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Rafati S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice. Parasite Immunol 2011; 33:335-48; PMID:21410716; DOI:10.1111/j.1365-3024.2011.01289.x.
127. Danesh-Bahreini MA, Shokri J, Samiei A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohammadi-Samani S. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int J Nanomedicine 2011; 6:835-42; PMID:21589651.
128. Colpitts SL, Dalton NM, Scott P. IL-7 receptor expression provides the potential for long-term survival of both CD62Lhigh central memory T cells and Th1 effector cells during Leishmania major infection. J Immunol 2009; 182:5702-11; PMID:19380817; DOI:10.4049/jimmunol.0803450.
129. + T cells. Infect Immun 1993; 61:3730-8; PMID:8359894.
130. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-50; PMID:17558415; DOI:10.1038/nm1592.
131. Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M, et al. IL-10 production differentially influences the magnitude, quality and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 2010; 207:1421-33; PMID:20530206; DOI:10.1084/jem.20092532.
132. Handman E, Button LL, McMaster RW. Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp Parasitol 1990; 70:427-35; PMID:2182337; DOI:10.1016/0014- 4894(90)90127-X.
133. Olobo JO, Anjili CO, Gicheru MM, Mbati PA, Kariuki TM, Githure JI, et al. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63). 199-212; PMID:8747903; DOI:10.1016/0304-4017(95)00788-6.
134. Rivier D, Bovay P, Shah R, Didisheim S, Mauel J. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunol 1999; 21:461-73; PMID:10476055; DOI:10.1046/j.1365- 3024.1999.00244.x.
135. Abdelhak S, Louzir H, Timm J, Blel L, Benlasfar Z, Lagranderie M, et al. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 1995; 141:1585-92; PMID:7551026; DOI:10.1099/13500872-141-7-1585.
136. González CR, Noriega FR, Huerta S, Santiago A, Vega M, Paniagua J, et al. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine 1998; 16:1043-52; PMID:9682357; DOI:10.1016/S0264-410X(97)00267-3.
137. Xu D, Liew FY. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 1995; 84:173-6; PMID:7750991.
138. Dumonteil E, Maria Jesus RS, Javier EO, Maria del Rosario GM. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 2003; 21:2161-8; PMID:12706707; DOI:10.1016/S0264-410X(02)00769-7.
139. Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YA, Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 2003; 170:3171-9; PMID:12626575.
140. Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 2004; 22:1631-9; PMID:15068845; DOI:10.1016/j.vaccine.2003.10.046.
141. Gonzalo RM, Rodriguez JR, Rodriguez D, Gonzalez-Aseguinolaza G, Larraga V, Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect 2001; 3:701-11; PMID:11489418; DOI:10.1016/S1286-4579(01)01426- 5.
142. Soussi N, Milon G, Colle JH, Mougneau E, Glaichenhaus N, Goossens PL. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/ LACK antigen of Leishmania major. Infect Immun 2000; 68:1498-506; PMID:10678966; DOI:10.1128/ IAI.68.3.1498-506.2000.
143. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D. Heterologous primeboost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 2005; 73:5286-9; PMID:16041057; DOI:10.1128/ IAI.73.8.5286-9.2005.
144. Ramiro MJ, Zarate JJ, Hanke T, Rodriguez D, Rodriguez JR, Esteban M, et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 2003; 21:2474-84; PMID:12744881; DOI:10.1016/S0264-410X(03)00032-X.
145. Tapia E, Perez-Jimenez E, Lopez-Fuertes L, Gonzalo R, Gherardi MM, Esteban M. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 2003; 5:73-84; PMID:12650765; DOI:10.1016/S1286- 4579(02)00077-1.
146. Lange UG, Mastroeni P, Blackwell JM, Stober CB. DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 2004; 72:4924-8; PMID:15271962; DOI:10.1128/IAI.72.8.4924-8.2004.
147. Pinto EF, Pinheiro RO, Rayol A, Larraga V, Rossi- Bergmann B. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. Infect Immun 2004; 72:4521-7; PMID:15271911; DOI:10.1128/IAI.72.8.4521-7.2004.
148. Rafati S, Baba AA, Bakhshayesh M, Vafa M. Vaccination of BALB/c mice with Leishmania major amastigotespecific cysteine proteinase. Clin Exp Immunol 2000; 120:134-8; PMID:10759774; DOI:10.1046/j.1365-2249.2000.01160.x.
149. Sukumaran B, Tewary P, Saxena S, Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 2003; 21:1292-9; PMID:12559811; DOI:10.1016/S0264-410X(02)00352-3.
150. Vélez ID, Gilchrist K, Martinez S, Ramirez- Pineda JR, Ashman JA, Alves FP, et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2009; 28:329-37; PMID:19879995; DOI:10.1016/j.vaccine. 2009.10.045.